Premium
Serum hepatocyte growth factor activator inhibitor type I (HAI‐I) and type 2 (HAI‐2) in prostate cancer
Author(s) -
Nagakawa Osamu,
Yamagishi Toshiya,
Akashi Takuya,
Nagaike Kazuhiro,
Fuse Hideki
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20301
Subject(s) - prostate cancer , medicine , prostate , hyperplasia , cancer , metastasis , hepatocyte growth factor , gastroenterology , endocrinology , oncology , receptor
BACKGROUND Hepatocyte growth factor activator inhibitor type 1 (HAI‐1) and type 2 (HAI‐2) are Kunitz‐type serine protease inhibitors for hepatocyte growth factor activator (HGFA). We attempted to clarify whether serum levels of HAI‐1 and HAI‐2 could be a useful marker in patients with prostate cancer. METHODS Serum levels of HAI‐1 and HAI‐2 were measured by enzyme‐linked immunosorbent assay in 27 patients with benign prostatic hyperplasia (BPH) and 118 patients with prostate cancer. RESULTS The mean serum levels of HAI‐1 in patients with prostate cancer were significantly higher than those in patients with BPH. Furthermore, the serum HAI‐1 levels in patients with distant metastasis and hormone resistant prostate cancer were significantly elevated compared with those in patients with organ‐confined diseases. There were no significant differences in serum HAI‐2 levels among prostate cancer subgroups according to clinical stage. Significantly elevated levels of HAI‐1 were detected in 38 patients with prostate cancer before any treatment. CONCLUSIONS HAI‐1 may be a potential tumor marker for prostate cancer. Further studies in large groups of patients are needed to define the clinical value of HAI‐1. © 2005 Wiley‐Liss, Inc.